The enteric nervous system (ENS), often called the "second brain," is a complex network of neurons embedded in the lining of the gastrointestinal (GI) tract. This extensive neural network plays a critical role in regulating digestion, gut motility, and communication with the central nervous system (CNS) through the vagus nerve[1]. In Parkinson's disease (PD), enteric neurons are among the earliest targets of alpha-synuclein pathology, appearing years before the characteristic motor symptoms emerge[2]. This page explores the anatomy, function, and clinical significance of enteric neurons in PD progression.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0007011 | enteric neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0007011 | enteric neuron | Medium |
The ENS contains approximately 100 million neurons organized into two major plexuses[3]:
Enteric neurons are diverse and include[6]:
The ENS communicates bidirectionally with the CNS via multiple pathways[11]:
The progressive distribution of Lewy bodies follows a predictable pattern in PD[16]:
Several hypotheses explain how α-syn pathology spreads from the gut to the brain[20]:
Post-mortem studies have consistently demonstrated[24]:
GI dysfunction is among the most common non-motor symptoms of PD[28]:
| Symptom | Prevalence | Onset |
|---|---|---|
| Constipation | 50-80% | 5-10 years before diagnosis |
| Gastroparesis | 30-50% | Early disease |
| Dysphagia | 20-40% | Mid-late disease |
| Fecal incontinence | 10-30% | Advanced disease |
The accessibility of enteric neurons makes them attractive for biomarker development[29]:
Targeting the gut-brain axis represents a promising therapeutic approach[33]:
Several trials are investigating ENS-based interventions[38]:
](/brain-regions/alpha-synuclein-pathway
--gut-brain-axis-in-neurodegeneration
--braak-staging
--dopamine
--vagus-nerve)## External Links
Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol. 2012. ↩︎
Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006. ↩︎
Gershon MD. The enteric nervous system: a second brain. Hosp Pract (Minneap). 2013. ↩︎
Huizinga JD, Lammers WJ. Gut peristalsis is governed by a multitude of cooperating mechanisms. Am J Physiol Gastrointest Liver Physiol. 2009. ↩︎
Furness JB. The organisation of the autonomic nervous system: peripheral and central interactions. J Auton Nerv Syst. 2012. ↩︎
Costa M, Brookes SJ, Hennig GW. Anatomy and physiology of the enteric nervous system. Gut. 2000. ↩︎
Galligan JJ. Pharmacology of synaptic transmission in the enteric nervous system. Curr Opin Pharmacol. 2002. ↩︎
Stark ME, Szurszewski JH. Role of nitric oxide as a mediator of gastrointestinal function and disease. Gastroenterology. 1992. ↩︎
Bitan A, Bak A, Polak O, et al. Vasoactive intestinal peptide and related peptides in the gastrointestinal tract: expression and biological functions. J Mol Neurosci. 2022. ↩︎
Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013. ↩︎
Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012. ↩︎
Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci. 2018. ↩︎
Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci. 2000. ↩︎
Sweeney P, O'Hara J, Xu Z, Yang Y. Brain regulation of energy balance and food intake. J Clin Invest. 2023. ↩︎
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008. ↩︎
Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003. ↩︎
Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007. ↩︎
Del Tredici K, Braak H. A not entirely benign procedure: progression of Parkinson's disease. Acta Neuropathol. 2008. ↩︎
Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014. ↩︎
Liddle RA. Parkinson's disease from the gut. Neuron. 2018. ↩︎
Brundin P, Melki R. Prying into the prion-like properties of misfolded α-synuclein. J Parkinsons Dis. 2017. ↩︎
Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014. ↩︎
Santos SF, de Lartigue G. Contribution of enteric glia to gastrointestinal motility disorders in Parkinson's disease. Neural Regen Res. 2022. ↩︎
Beach TG, Adler CH, Lue LF, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009. ↩︎
Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012. ↩︎
Stoker TB, Torsney KM, Barker RA. Enteric alpha-synuclein and gastrointestinal motility in Parkinson's disease. Mov Disord. 2018. ↩︎
Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015. ↩︎
Jost WH. Gastrointestinal aspects in Parkinson's disease. J Neurol Sci. 2020. ↩︎
Visanji NP, Marras C, Kern DS, et al. Colonic involvement in early Parkinson disease: implications for disease biomarkers. Neurology. 2017. ↩︎
Sprouse DR, Zhang L, Chen W, et al. Phosphorylated α-synuclein in colonic mucosa: a biomarker for prodromal Parkinson's disease? Parkinsonism Relat Disord. Parkinsonism Relat Disord. 2022. ↩︎
Mulak A, Bonaz B. Gut-brain axis in Parkinson's disease: the role of gut microbiota. J Neurogastroenterol Motil. 2015. ↩︎
Nuzum ND, Loughman A, Szymlek-Gay EA, et al. Gut microbiota and volatile fatty acids in Parkinson's disease. NPJ Parkinsons Dis. 2022. ↩︎
Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016. ↩︎
Bridi JC, Hirth F. Mechanisms of α-synuclein implicated in Parkinson's disease. Mol Neurobiol. 2018. ↩︎
Zhou ZL, Lin J, Huang Y, et al. Effects of probiotic supplementation on gastrointestinal symptoms in Parkinson's disease: a randomized controlled trial. Front Neurol. 2022. ↩︎
Chen Y, Liu J, Wang Y, et al. Anti-inflammatory therapy for Parkinson's disease: a focus on gut. Front Aging Neurosci. 2023. ↩︎
Howland RH. Vagus nerve stimulation. Curr Behav Neurosci Rep. 2014. ↩︎
ClinicalTrials.gov. Clinical trials targeting gut-brain axis in Parkinson's disease. ClinicalTrials.gov. ↩︎
ClinicalTrials.gov. NCT05468190: Biomarkers in early Parkinson's disease. ClinicalTrials.gov. ↩︎
ClinicalTrials.gov. NCT05243550: Alpha-synuclein detection in intestinal biopsies. ClinicalTrials.gov. ↩︎
ClinicalTrials.gov. NCT04877340: Probiotic supplementation in Parkinson's disease. ClinicalTrials.gov. ↩︎